DermTech: Carcinome Clinical Study Enrollment Complete

May 28, 2018

DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study. The goal of the Carcinome™ study is to develop a non-invasive genomic test to differentiate basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) from non-cancerous lesions like actinic keratosis. More than 600 patients were enrolled in this study.

Over 4 million cases of BCC and 1 million cases of SCC are diagnosed each year in the US, with more than 13 million surgical biopsies performed to diagnose these non-melanoma skin cancers. Carcinome™ is the third non-invasive skin cancer test being developed by DermTech using their proprietary molecular pathology platform technology.

“We are excited to complete this phase of the study and look forward to Carcinome’s™ full validation to successfully distinguish BCC and SCC from non-cancerous lesions, all with skin tissue collected non-invasively using adhesive patches,” said Zuxu Yao, PhD, DermTech’s Chief Scientific Officer and head of Research and Development.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free